Richard Scott Struthers net worth and biography

Richard Struthers Biography and Net Worth

R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, and he has served on its board of directors since January 2009.

He obtained both his undergraduate and Ph.D. degrees from the University of California, San Diego.

What is Richard Scott Struthers' net worth?: The estimated net worth of Richard Scott Struthers is at least $11.54 million as of March 19th, 2025. Dr. Struthers owns 329,147 shares of Crinetics Pharmaceuticals stock worth more than $11,543,185 as of March 26th. This net worth evaluation does not reflect any other investments that Dr. Struthers may own. Learn More about Richard Scott Struthers' net worth.
How do I contact Richard Scott Struthers?: The corporate mailing address for Dr. Struthers and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at ir@crinetics.com. Learn More on Richard Scott Struthers' contact information.
Has Richard Scott Struthers been buying or selling shares of Crinetics Pharmaceuticals?: Over the course of the past ninety days, Richard Scott Struthers has sold $592,959.60 in shares of Crinetics Pharmaceuticals stock. Most recently, Richard Scott Struthers sold 17,338 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $34.20, for a transaction totalling $592,959.60. Following the completion of the sale, the chief executive officer now directly owns 329,147 shares of the company's stock, valued at $11,256,827.40. Learn More on Richard Scott Struthers' trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), Coelho Vivaldi (Director), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 27 times. They sold a total of 429,216 shares worth more than $20,665,037.89. The most recent insider tranaction occured on March, 19th when insider Dana Pizzuti sold 2,515 shares worth more than $86,013.00. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 3/19/2025.

Richard Scott Struthers Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2025	Sell	17,338	$34.20	$592,959.60	329,147
5/8/2024	Sell	107,448	$49.40	$5,307,931.20	257,485
4/4/2024	Sell	40,951	$49.17	$2,013,560.67	237,835
11/3/2023	Sell	199,082	$30.56	$6,083,945.92	135,522
7/13/2023	Sell	14,157	$20.35	$288,094.95	630,805
7/11/2023	Sell	24,384	$20.14	$491,093.76	656,421
6/16/2023	Sell	50,000	$20.81	$1,040,500.00	680,805
4/13/2022	Sell	138,643	$26.83	$3,719,791.69	730,805
4/5/2022	Sell	21,357	$25.34	$541,186.38	57,400
9/7/2021	Sell	30,000	$25.00	$750,000.00
12/2/2020	Buy	1,000	$12.60	$12,600.00	4,000
7/15/2020	Sell	17,500	$15.30	$267,750.00

Richard Scott Struthers Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $35.07

$34.47

$36.45

50 Day Range

MA: $36.15

$32.30

$40.40

2 Week Range

Now: $35.07

$31.84

$62.53

Volume

1,036,194 shs

Average Volume

816,004 shs

Market Capitalization

$3.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58